Loading...
NBRV.F logo

Nabriva Therapeutics plcOTCPK:NBRV.F Stock Report

Market Cap US$323.0
Share Price
n/a
1Y0%
7D0%
1D0%
Portfolio Value
​
View

Nabriva Therapeutics plc

OTCPK:NBRV.F Stock Report

Market Cap: US$323.0

Nabriva Therapeutics (NBRV.F) Stock Overview

A biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. More details

NBRV.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($323)

Shares are highly illiquid

Latest financial reports are more than a year old


NBRV.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW496,749 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
496,749 investors already sharing narratives
View all narratives

Nabriva Therapeutics plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Nabriva Therapeutics
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$0.0002
52 Week LowUS$0.000001
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Change0%
3 Year Change-99.90%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 15

Nabriva Therapeutics to effect 1-for-25 reverse stock split

Biopharmaceutical company Nabriva Therapeutics (NASDAQ:NBRV) is set to effect a 1-for-25 reverse stock split, effective for trading purposes on the Nasdaq Capital Market as of Sep. 16. The company's shareholders approved the stock split at the annual general meeting of the shareholders on Aug. 11. The split is still subject to and conditional upon the board determining that the action is necessary for compliance with the minimum $1.00 per share requirement of Nasdaq. The shares will continue to trade on the stock exchange under the symbol NBRV. The reverse stock split will reduce the number of outstanding ordinary shares to ~2.8M from ~69.7M and reduce the number of authorized ordinary shares to 12M from 300M. NBRV shares were trading +63.24% pre-market. Source: Press Release
Seeking Alpha • Jul 18

Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta

Nabriva Therapeutics (NASDAQ:NBRV) signed a distribution agreement with Er-Kim for the oral and intravenous formulations of its medicine Xenleta (lefamulin). Xenleta is used to treat adults with community-acquired bacterial pneumonia. Under the agreement, Er-Kim gains exclusive rights to distribute Xenleta in Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia. Ireland-based Nabriva said Er-Kim also may distribute the drug to an additional five countries through a Named Patient Usage (NPU) program. Nabriva noted that it will be the exclusive supplier of the therapy to Er-Kim. NBRV +19.12% to $0.23 premarket July 18
Analysis Article • Apr 04

Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022

One thing we could say about the analysts on Nabriva Therapeutics plc ( NASDAQ:NBRV ) - they aren't optimistic, having...
Analysis Article • Aug 11

Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts

Shareholders in Nabriva Therapeutics plc ( NASDAQ:NBRV ) may be thrilled to learn that the analysts have just delivered...
Analysis Article • Jul 22

We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation

The underwhelming share price performance of Nabriva Therapeutics plc ( NASDAQ:NBRV ) in the past three years would...
Analysis Article • Feb 16

When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?

We feel now is a pretty good time to analyse Nabriva Therapeutics plc's ( NASDAQ:NBRV ) business as it appears the...

Shareholder Returns

NBRV.FUS PharmaceuticalsUS Market
7D0%1.4%1.6%
1Y0%48.6%18.6%

Return vs Industry: NBRV.F underperformed the US Pharmaceuticals industry which returned 48.6% over the past year.

Return vs Market: NBRV.F underperformed the US Market which returned 18.6% over the past year.

Price Volatility

Is NBRV.F's price volatile compared to industry and market?
NBRV.F volatility
NBRV.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: NBRV.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine NBRV.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005n/aH. Hoganwww.nabriva.com

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); XENLETA for the treatment of community-acquired bacterial pneumonia; and CONTEPO for the treatment of complicated urinary tract infections, including acute pyelonephritis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007.

Nabriva Therapeutics plc Fundamentals Summary

How do Nabriva Therapeutics's earnings and revenue compare to its market cap?
NBRV.F fundamental statistics
Market capUS$323.00
Earnings (TTM)-US$55.05m
Revenue (TTM)US$29.56m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is NBRV.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NBRV.F income statement (TTM)
RevenueUS$29.56m
Cost of RevenueUS$47.66m
Gross Profit-US$18.11m
Other ExpensesUS$36.95m
Earnings-US$55.05m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did NBRV.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 08:03
End of Day Share Price 2026/06/15 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nabriva Therapeutics plc is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Chiara RussoCantor Fitzgerald & Co.
Antonio ArceH.C. Wainwright & Co.